Excelsior Advisor Network LLC Makes New Investment in United Therapeutics Corporation $UTHR

Excelsior Advisor Network LLC acquired a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 979 shares of the biotechnology company’s stock, valued at approximately $581,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Torren Management LLC purchased a new position in shares of United Therapeutics in the 4th quarter worth $26,000. Activest Wealth Management grew its stake in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the period. WealthCollab LLC increased its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its position in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new position in shares of United Therapeutics during the 4th quarter valued at $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $535.99, for a total transaction of $5,091,905.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $21,714,562.87. The trade was a 19.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jan Malcolm sold 325 shares of the company’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $550.59, for a total transaction of $178,941.75. Following the completion of the transaction, the director owned 450 shares of the company’s stock, valued at approximately $247,765.50. This trade represents a 41.94% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 493,833 shares of company stock worth $275,841,047. 8.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on UTHR shares. Royal Bank Of Canada increased their price target on United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. HC Wainwright increased their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Bank of America reduced their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Raymond James Financial began coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective on the stock. Finally, Morgan Stanley set a $516.00 target price on United Therapeutics in a research report on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $648.33.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $527.94 on Tuesday. The company has a 50-day simple moving average of $547.10 and a 200-day simple moving average of $531.86. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The firm has a market capitalization of $22.41 billion, a PE ratio of 19.49, a price-to-earnings-growth ratio of 1.77 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same period last year, the company posted $6.63 earnings per share. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. Equities analysts forecast that United Therapeutics Corporation will post 26.65 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.